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Background
MEDI4736 is an engineered human IgG1 that blocks
PD-L1 binding to PD-1 and allows T-cells to recognize
and kill tumor. MEDI4736 has single-agent activity and
potential for further increased activity in combination. A
comprehensive development programme is underway in
NSCLC, as monotherapy and in combination.
Methods
NSCLC data from 2 multicentre, open-label Phase I stu-
dies are reported. NCT01693562 evaluates safety and effi-
cacy of MEDI4736 administered every 2 or 3 weeks.
NCT02000947 evaluates safety and efficacy of MEDI4736
in combination with tremelimumab, a human IgG2 anti-
CTLA-4 mAb, at 4-week intervals.
Results
NCT01693562: As of May 2014, NSCLC cohort
included 155 patients (pts) (median age 65 years [33-
85], PS 0/1/unknown [25%/73%/2%], median 3 [0-7]
prior treatments). Median follow-up: 6 weeks (range 0-
67). Treatment-related adverse events (TRAEs): 29%
(Grade [Gr] ≥3: 3%); none led to treatment discontinua-
tion. Most frequent TRAEs: fatigue (7%), nausea (5%),
and vomiting (5%). No treatment-related colitis any Gr.
No treatment-related Gr 3/4 pneumonitis or dyspnea.
58 pts had ≥12 weeks follow-up: 16% had partial
response (as early as 6 weeks), duration of response ran-
ged 5-54+ weeks, disease control rate 35%. PD-L1 posi-
tivity appears to enrich for response.
NCT02000947: As of April, 2014, 12 pts treated at 4
dose-levels (PS 0-1, median 3 [2-5] prior treatments). No
DLTs observed in any cohort during DLT observation per-
iod. Most frequent TRAEs: -↑amylase, abdominal pain,
arthralgia, colitis, diarrhea, epigastric discomfort, fatigue
and nausea. TRAEs ≥Gr 3 noted in 3 pts: Gr 3 - ↑AST/
ALT & Gr 5 myasthenia (MG) (n = 1), Gr 3 diarrhea/coli-
tis (n = 1), Gr 4 - ↑amylase (n = 1). TRAEs led to disconti-
nuation in two subjects: Gr 5 MG and Gr3 colitis. In 12
response-evaluable pts (Figure 1), tumor shrinkage at 8
weeks: 0/3 pts cohort 1a; 6/9 pts cohorts 2a and 3a/b; dis-
ease control: 7/12 pts. Dose-escalation ongoing; total of 6
dose-levels, including cohort 5a (MEDI4736/Treme: 15/10
mg/kg), has been cleared since cut-off.
Conclusions
Current safety profile and encouraging early antitumor
activity (monotherapy and combination) support continued
development in NSCLC. Additional monotherapy NSCLC
studies: Phase II ‘ATLANTIC’ (NCT02087423), Phase III
‘PACIFIC’ following chemo-radiotherapy (NCT02125461),
Combination: Phase I + gefitinib (NCT02088112), and
Phase Ib + AZD9291 (NCT02143466). Monotherapy and
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Figure 1 Red: Cohort1a (MEDI4735/Treme: 3/1); Green: Cohort 2a (MEDI4736/Treme 10/1); Gold: Cohort 3a (MEDI4736/Treme 15/1);
Blue: Cohort 3b (MEDI4736/Treme 10/3).
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